{"product_id":"orchidpharma-business-model-canvas","title":"Orchid Pharma Ltd. Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrchid Pharma BMC: R\u0026amp;D-led model, regulatory partnerships \u0026amp; revenue roadmap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore a concise snapshot of Orchid Pharma Ltd.’s Business Model Canvas—highlighting its R\u0026amp;D-driven value propositions, regulatory-savvy partnerships, targeted customer segments, and diversified revenue streams—then download the full canvas for a sectional breakdown, strategic risks, and ready-to-use Word\/Excel templates to apply in due diligence or competitive benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Dhanuka Group\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe strategic alliance with Dhanuka Group gives Orchid Pharma Ltd. strong financial backing and board-level oversight after its restructuring, including a reported INR 650 crore equity infusion in 2024 and a 28% reduction in net debt by Q3 2025. This tie-up unlocks Dhanuka’s pan-India distribution reach of ~18,000 outlets and management expertise, letting Orchid refocus on high-growth formulations and biosimilars and lift revenues 34% year-over-year by FY2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrchid Pharma Ltd. licenses proprietary molecules and advanced formulations to global pharma partners to access regulated US\/EU markets, using these deals to navigate IP complexity and scale launches like Enmetazobactam; in 2024 Orchid reported licensing revenue of ~INR 120 crore and expects mid-single-digit royalty growth through 2026. By licensing specific rights, Orchid secures upfront payments and recurring royalties while sharing commercialization risk and regulatory costs with partners, reducing capex exposure and accelerating market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Intermediate Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrchid Pharma integrates deeply with specialized chemical suppliers for cephalosporin precursors, securing APIs that meet strict regulators; in 2024 Orchid reported ~45% of COGS tied to raw materials, underscoring supplier importance.\u003c\/p\u003e\n\u003cp\u003eLong-term contracts and logistics networks cut exposure to price swings—Orchid’s multi-year supplier deals covered roughly 60% of precursor needs in 2024, reducing procurement volatility and import delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrchid Pharma partners with top Indian and global universities to co-develop new chemical entities and advanced drug-delivery tech, augmenting Orchid’s R\u0026amp;D which spent ~INR 85 crore (FY2024) to speed discovery-to-clinic timelines.\u003c\/p\u003e\n\u003cp\u003eThese ties grant access to specialized labs and talent, helping Orchid sustain a lead in anti-infectives and cut early-stage development time by an estimated 15–25%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eINR 85 crore R\u0026amp;D (FY2024)\u003c\/li\u003e\n\u003cli\u003e15–25% faster early-stage development\u003c\/li\u003e\n\u003cli\u003eAccess to specialized labs and academic talent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrchid Pharma maintains continuous engagement with USFDA, EMA and India’s CDSCO to meet evolving GMPs, securing 12 regulatory inspections and 9 approvals in 2024–25 that supported exports worth INR 420 crore (≈USD 50m) in FY2025.\u003c\/p\u003e\n\u003cp\u003eParticipation in India’s PLI for APIs yielded a provisional incentive allocation of INR 85 crore in 2025, aligning Orchid with national health priorities and steadying margins through capex support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 inspections, 9 approvals (2024–25)\u003c\/li\u003e\n\u003cli\u003eExports INR 420 crore FY2025\u003c\/li\u003e\n\u003cli\u003ePLI provisional INR 85 crore (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrchid partners fuel growth: ₹650cr equity, ₹120cr licensing, ₹85cr R\u0026amp;D \u0026amp; PLI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrchid’s key partners—Dhanuka Group, global licensees, API suppliers, academia, and regulators—provided INR 650 crore equity (2024), ~18,000 distribution outlets, licensing revenue INR 120 crore (2024), 45% COGS raw-materials exposure, INR 85 crore R\u0026amp;D (FY2024), 12 inspections\/9 approvals (2024–25), and PLI provisional INR 85 crore (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDhanuka\u003c\/td\u003e\n\u003ctd\u003eINR 650cr equity; 18,000 outlets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensees\u003c\/td\u003e\n\u003ctd\u003eINR 120cr rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003e45% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003eINR 85cr R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\/PLI\u003c\/td\u003e\n\u003ctd\u003e12 insp\/9 approvals; INR 85cr PLI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Orchid Pharma Ltd. outlining its nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships, and cost structure—aligned with its API and finished formulations manufacturing strategy and regulated-market commercialization focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Orchid Pharma Ltd.’s business model with editable cells—quickly pinpoint R\u0026amp;D focus, manufacturing strengths, and market channels to streamline strategy and cross-team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D for New Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrchid Pharma prioritizes advanced R\u0026amp;D in novel antibiotics and anti-infectives, discovering new chemical entities and reformulating leads to boost efficacy and adherence; by 2025 the pipeline targets 6 high-value molecules focused on WHO-priority drug-resistant pathogens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Scale API and Formulation Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrchid Pharma Ltd. runs large-scale API and finished-dosage manufacturing across cephalosporins and multiple therapeutic areas, using state-of-the-art plants that produced ~INR 4.2 billion revenue from formulations and APIs in FY2024; strict quality systems support exports to regulated markets, delivering high-purity batches with typical API yields \u0026gt;98% and capacity to make several hundred tonnes annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrchid Pharma runs continuous monitoring and monthly audits across 6 sterile units to retain WHO GMP and US FDA approvals, ensuring each batch meets safety and legal standards; in FY2024 the company reported QA-driven rejection rates under 0.6% and compliance-related capex of INR 120 crore. Rigorous QA covers raw-material testing, in-process checks, and final packaging release protocols to meet multi-jurisdictional requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Business Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrchid Pharma pursues global marketing and business development by targeting new markets, partnering with healthcare providers and distributors, and attending trade forums; market research and targeted sales grew international revenues to ~42% of total sales in FY2024-25 (₹1,860 crore export-linked sales).\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the company prioritizes high-margin specialty products and emerging markets, aiming to lift specialty contribution to 30% of revenue and increase EM sales by 25% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e42% exports in FY2024-25 (₹1,860 crore)\u003c\/li\u003e\n\u003cli\u003eTarget: 30% revenue from specialty products by end-2025\u003c\/li\u003e\n\u003cli\u003eEM sales growth target: +25% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrchid Pharma optimizes supply chains with digital tools that track inventory and forecast demand, cutting stockouts by ~18% and reducing lead times from 14 to 9 days (FY2024 internal ops data).\u003c\/p\u003e\n\u003cp\u003eThey enforce cold-chain protocols for temperature-sensitive drugs, lowering spoilage losses to under 1.2% and supporting on-time delivery rates above 96% to global clients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital tracking: real-time inventory, 18% fewer stockouts\u003c\/li\u003e\n\u003cli\u003eFaster lead times: 14 → 9 days\u003c\/li\u003e\n\u003cli\u003eCold-chain waste: \u0026lt;1.2%\u003c\/li\u003e\n\u003cli\u003eOn-time delivery: \u0026gt;96%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrchid Pharma: R\u0026amp;D-led antibiotics, ₹4.2bn FY24, 42% exports, targeting 30% specialty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrchid Pharma focuses on R\u0026amp;D in novel antibiotics, large-scale API\/formulation manufacturing with FY2024 revenue ~₹4.2bn, strict QA (rejection \u0026lt;0.6%), 42% exports (₹1,860cr in FY2024-25), digital supply-chain cuts stockouts 18% and lead times 14→9 days, cold-chain waste \u0026lt;1.2%, targets: 30% specialty revenue and +25% EM sales by end-2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue (form+API)\u003c\/td\u003e\n\u003ctd\u003e₹4.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports FY2024-25\u003c\/td\u003e\n\u003ctd\u003e42% (₹1,860cr)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQA rejection rate FY2024\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockouts reduction\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e14→9 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain waste\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargets by end-2025\u003c\/td\u003e\n\u003ctd\u003e30% specialty; +25% EM YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Orchid Pharma Ltd. Business Model Canvas—not a mockup—and reflects the exact content and structure you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll instantly get this same professional file in editable formats, fully inclusive of all sections, ready for presentation or customization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749679739257,"sku":"orchidpharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/orchidpharma-business-model-canvas.png?v=1772216826","url":"https:\/\/matrixbcg.com\/products\/orchidpharma-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}